Your browser is no longer supported. Please, upgrade your browser.
Adverum Biotechnologies, Inc.
Index- P/E- EPS (ttm)-1.44 Insider Own1.40% Shs Outstand98.02M Perf Week-5.34%
Market Cap198.78M Forward P/E- EPS next Y-1.28 Insider Trans-0.33% Shs Float96.16M Perf Month-14.47%
Income-138.20M PEG- EPS next Q-0.37 Inst Own73.90% Short Float7.94% Perf Quarter-19.75%
Sales7.50M P/S26.50 EPS this Y-37.20% Inst Trans-9.22% Short Ratio3.21 Perf Half Y-80.42%
Book/sh3.87 P/B0.50 EPS next Y12.90% ROA-27.90% Target Price3.57 Perf Year-84.13%
Cash/sh3.57 P/C0.55 EPS next 5Y- ROE-32.60% 52W Range1.99 - 14.79 Perf YTD-82.01%
Dividend- P/FCF- EPS past 5Y5.80% ROI- 52W High-86.82% Beta1.10
Dividend %- Quick Ratio18.80 Sales past 5Y- Gross Margin- 52W Low-2.01% ATR0.11
Employees167 Current Ratio18.80 Sales Q/Q- Oper. Margin- RSI (14)36.11 Volatility3.19% 5.37%
OptionableYes Debt/Eq0.00 EPS Q/Q-24.30% Profit Margin- Rel Volume0.56 Prev Close2.00
ShortableYes LT Debt/Eq0.00 EarningsAug 05 AMC Payout- Avg Volume2.38M Price1.95
Recom2.90 SMA20-8.81% SMA50-12.88% SMA200-68.33% Volume1,329,012 Change-2.50%
Jul-23-21Downgrade Cantor Fitzgerald Overweight → Neutral
May-03-21Downgrade SVB Leerink Outperform → Mkt Perform $5
Apr-29-21Downgrade Truist Buy → Hold $30 → $9
Apr-29-21Downgrade RBC Capital Mkts Outperform → Sector Perform $6
Apr-29-21Downgrade Chardan Capital Markets Buy → Neutral $5
Dec-16-20Initiated UBS Neutral $13
Nov-12-20Upgrade Raymond James Underperform → Mkt Perform
Jun-26-20Downgrade Raymond James Mkt Perform → Underperform
May-13-20Initiated RBC Capital Mkts Outperform $24
May-05-20Upgrade SunTrust Hold → Buy $13 → $21
Apr-28-20Initiated Goldman Buy $17
Mar-16-20Initiated SVB Leerink Outperform $17
Feb-10-20Upgrade Chardan Capital Markets Neutral → Buy $20
Feb-10-20Upgrade Cantor Fitzgerald Neutral → Overweight $8 → $21
Oct-15-19Reiterated Chardan Capital Markets Neutral $6 → $10
Sep-13-19Reiterated Chardan Capital Markets Neutral $10 → $6
Jun-14-19Resumed Raymond James Mkt Perform
Nov-02-18Downgrade SunTrust Buy → Hold
Nov-02-18Downgrade Raymond James Outperform → Mkt Perform
Sep-21-18Initiated Cantor Fitzgerald Overweight
Oct-09-21 11:17AM  
Oct-05-21 05:17AM  
Oct-04-21 02:31PM  
Oct-03-21 08:14AM  
Oct-01-21 04:00PM  
Sep-27-21 09:00AM  
Aug-23-21 09:00AM  
Aug-19-21 07:05AM  
Aug-06-21 10:19AM  
Aug-05-21 04:05PM  
Jul-22-21 04:05PM  
Jul-19-21 02:49PM  
Jul-01-21 08:00AM  
Jun-28-21 12:00PM  
Jun-24-21 04:05PM  
Jun-21-21 01:22AM  
Jun-07-21 10:00AM  
Jun-01-21 08:00AM  
May-18-21 08:44AM  
May-17-21 12:17PM  
May-12-21 03:17PM  
May-11-21 03:15PM  
May-10-21 10:41AM  
May-06-21 05:15PM  
May-04-21 08:30AM  
May-03-21 06:07AM  
May-01-21 03:26PM  
Apr-29-21 02:58PM  
Apr-28-21 04:01PM  
Apr-26-21 09:00AM  
Apr-22-21 05:00PM  
Apr-21-21 08:00AM  
Apr-19-21 04:10PM  
Apr-16-21 08:05AM  
Apr-15-21 08:00AM  
Apr-08-21 09:39AM  
Mar-30-21 09:00AM  
Mar-18-21 04:00PM  
Mar-17-21 05:10PM  
Mar-05-21 08:30AM  
Mar-02-21 07:31AM  
Mar-01-21 05:25PM  
Feb-22-21 04:00PM  
Feb-18-21 04:00PM  
Feb-10-21 04:49PM  
Feb-02-21 09:00AM  
Jan-21-21 11:02PM  
Jan-11-21 12:00PM  
Jan-08-21 08:49AM  
Jan-07-21 11:57AM  
Jan-05-21 09:00AM  
Dec-21-20 10:23AM  
Dec-14-20 09:00AM  
Nov-23-20 11:00AM  
Nov-14-20 10:00AM  
Nov-08-20 07:32AM  
Nov-05-20 06:35PM  
Oct-20-20 09:00AM  
Oct-09-20 08:56AM  
Sep-29-20 05:23PM  
Sep-15-20 08:00AM  
Sep-10-20 08:00AM  
Sep-08-20 08:57AM  
Aug-20-20 07:57AM  
Aug-18-20 09:00AM  
Aug-17-20 08:51AM  
Aug-12-20 09:37PM  
Aug-11-20 04:01PM  
Aug-10-20 05:35PM  
Jul-29-20 04:05PM  
Jul-21-20 08:00AM  
Jul-20-20 11:07AM  
Jul-13-20 08:30AM  
Jul-06-20 09:00AM  
Jun-30-20 11:50PM  
Jun-25-20 04:01PM  
Jun-16-20 08:13AM  
Jun-15-20 04:01PM  
Jun-04-20 04:05PM  
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Clark JulieChief Medical OfficerSep 30Sale2.174,76610,342164,723Oct 04 05:36 PM
Fischer LaurentCEO and DirectorMar 24Buy9.8810,00098,78026,292Mar 24 07:47 PM
Machado PatrickDirectorMar 24Buy9.9210,00099,19688,182Mar 24 07:46 PM
PATTERSON LEONE DPresident and CFOFeb 09Sale14.1012,533176,71897,955Feb 11 07:47 PM
Machado PatrickDirectorJan 15Buy11.5210,000115,17478,182Jan 19 08:33 PM
Fischer LaurentCEO and DirectorJan 15Buy11.538,60099,19116,292Jan 19 08:32 PM